BRENTUXIMAB VEDOTIN VS PHYSICIAN'S CHOICE IN CTCL PATIENTS FROM THE PHASE 3 ALCANZA STUDY: ANALYSIS OF OUTCOMES BY CD30 EXPRESSION.

Authors :: Kim, Y.H.
Prince, H.M.
Whittaker, S.
Horwitz, S.M.
Duvic, M.
Scarisbrick, J.
Quaglino, P.
Zinzani, P.L.
Wolter, P.
Bechter, O.
Wang, Y.
Palanca ‐ Wessels, M.C.
Wood, K.W.
Li, M.
Liu, Y.
Lin, H.
Little, M.
Danaee, H.
Trepicchio, W.
Dummer, R.
Source :: Hematological Oncology; Jun2017 Supplement, Vol. 35, p77-78, 2p
Publication Year :: 2017

Full Text Access

Tools